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Table 1: Baseline Characteristics
Introduction: 
Patients with peripheral artery disease (PAD) are at very high risk of 
future cardiovascular events1,2. However, clinical experience suggests 
that PAD has a wide range of prognosis due to a different 
atherosclerotic extent with further vascular beds affected, i.e. coronary 
artery disease (CAD) and/ or cerebrovascular disease (CeVD)3. 
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72.0 ± 11.7 70.3 ± 12.4 73.2 ± 11.0 75.6 ± 8.9 < 0.0001
Female gender, 
n [%]
502 [36] 282 [41] 181 [33] 39 [28] < 0.01
CVD family 
history, n [%]
178 [13] 70 [10] 84 [15] 24 [18] < 0.01
Current smoker, 
n [%]
636 [46] 363 [53] 226 [41] 46 [34] < 0.0001
Diabetes, n [%] 419 [30] 165 [24] 194 [35] 60 [44] < 0.0001
Hypertension, n 
[%]




1012 [73] 449 [65] 456 [83] 109 [80] < 0.0001
Chronic Kidney 
disease (CKD), n 
[%]
954 [69] 430 [62] 414 [75] 110 [80] < 0.0001
Purpose: 
We hypothesized that patients with a polyvascular extent (+ 
CAD and/ or CeVD) of PAD have poorer prognosis compared 
to those with PAD alone.
Methods: 
Single center longitudinal observational study with symptomatic PAD 
patients over a period from 2009 to 2019. We related the 
atherosclerotic extent (PAD, +1 vascular region  (+/- CAD or 
CeVD)(+1V), +2 vascular regions (+ CAD and CeVD)(+2V) to all-
cause and cardiovascular mortality as well as to cardiovascular event 
rate. 
Results: 
 Polyvascular patients (+1V and +2V) were older and had more 
comorbidities compared to PAD only patients (Table 1). 
 Guideline conform secondary prevention therapy, in particular statin 
therapy was significantly lower in PAD than polyvascular patients 
(+1V and +2V; p< 0.001, Figure 1). 
 Despite of the more adequate treatment, all-cause and cardiovascular 
mortality and event rate was higher in polyvascular patients than in 
PAD only patients (Figure 2-4) 
Conclusion: 
PAD patients with a polyvascular involvement receive an adequate 
guideline conform treatment. Nevertheless, mortality is higher in this 
poulation. Our data suggest conversely, that an intensified treatment for 
PAD patients might help to avoid progression into a polyvascular disease 
and thus, an increased mortality in this population.
Figure 2: Kaplan-Meyer curves representing the influence of polyvascular extend on all-cause mortality
Figure 3: Kaplan-Meyer curves representing the influence of polyvascular extend on cardio-vascular mortality
Figure 4: Kaplan-Meyer curves representing the influence of polyvascular extend on cardio-vascular events
Figure 4: Percentage of statin therapy and intensity in PAD only and polyvascular patients
